Published: May 2021
The rapidly growing pipeline of genetically modified therapies reflects the surge in demand for high quality vectors, presenting lucrative opportunities for companies with the capabilities to manufacture viral and non-viral gene delivery solutions
Roots Analysis has announced the addition of “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition) 2021 – 2030” report to its list of offerings.
Over time, ~15 cell and gene therapies have been approved across the world. Since transgene delivery into biological producing cell lines, gene modified cell-based therapies and the body, is an indispensable aspect of modern drug / therapy development efforts, high quality vectors are required by both medical researchers, drug developers and manufact7uring service providers, alike. In order to save time and costs, many stakeholders in the cell and gene therapy market have opted to outsource their vector manufacturing needs.
To order this 685+ page report, which features 170+ figures and 290+ tables, please visit www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html
Key Market Insights
The market features the presence of over 225 industry players and non-industry players
It is currently dominated by the presence of mid-sized players (51-500 employees), which represent more than 55% of industry stakeholders, worldwide. Of these, ~80% are capable of synthesizing different types of viral vectors, and round 10% of the companies mentioned in the report claim to have expertise in manufacturing plasmid DNA.
Over the time, several new technology platforms have been developed to deal with existing production-related challenges
Majority (85%) of the available technologies are currently focused on viral vectors. The technology landscape analysis featured in the report, highlights the fact that 55% of the contemporary platforms are meant for the development and production of gene therapies.
Close to 210 partnerships were inked in this market, over the last five years
More than 55% of partnerships were inked post 2017, with the maximum activity being reported in 2020 (till September). Most of the deals (~27%) were manufacturing agreements, followed by product / technology licensing (24%), product development (17%) and R&D (9%) agreements.
Expansion activity in this domain has grown at a CAGR of 97%, between 2015 and 2020
Most of the reported expansions were related to the establishment of new facilities / plants (52%), followed by facility expansions (22%), indicative of the initiatives undertaken by service providers to cope with the rapidly increasing demand for good quality vectors.
The installed vector manufacturing capacity is estimated to be 63,000+ L
The majority share of the available vector manufacturing capacity belongs to companies with both clinical and commercial scale facilities (~70%). In fact, 65% of the estimated global vector producing capacity belongs to the larger and more established stakeholders in the market.
Till 2030, the annual demand for vectors is expected grow at an annualized rate of 21%
Currently, North America and Europe contribute to more than 70% of the demand for viral and non-viral vectors. By 2030, the demand, in terms of number of patients in need to interventions requiring some form of vector, is projected to be over 220,000.
The developed markets are likely to remain the major contributors, in terms of service revenues, to the market
The majority share of service revenues is anticipated to come from vector manufacturing project for oncological disorders (~55%). By 2030, the need for gene delivery solutions for commercialized therapies, is expected to be responsible for 60% of the annual service revenues, representing a CAGR of 39%.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/274/request-sample.html
Key Questions Answered
The USD 2.5+ billion (by 2030) financial opportunity associated with viral vector, non-viral vector and gene therapy manufacturing market has been analyzed across the following segments:
Scale of operation
Type of Vector
The report also features inputs from eminent industry stakeholders, according to whom, the anticipated increase in demand for cell and gene therapies, is the most prominent driver of the growth of the vector supply market. The report includes detailed transcripts of discussions held with the following experts:
The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), information related to its manufacturing facilities, proprietary vector manufacturing technology and an informed future outlook.
For additional details, please visit www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html or email email@example.com
You may also be interested in the following titles
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES